|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, we demonstrate that circMTO1 inhibits liver fibrosis via regulation of miR-17-5p and Smad7, and serum circMTO1 may be a novel promising biomarker of liver fibrosis.
|
31148365 |
2019 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of Smad7 in hepatocytes has been shown to promote liver fibrosis, but little is known about the effects of Smad7 in myeloid cells during inflammatory responses in the liver.
|
31698731 |
2019 |
|
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PZQ exhibited a strong efficacy against liver fibrosis by inhibiting HSCs activation via Smad7 upregulation, suggesting is potential broad utility in treatment of diseases characterized by liver fibrosis.
|
31412137 |
2019 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicate that miR-212-3p facilitates the activation of HSCs and TGF-β pathway by targeting SMAD7, highlighting that it can be served as a novel biomarker or therapeutic target for liver fibrosis.
|
29307832 |
2018 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study explored the effects of CGA on miR-21-regulated TGF-β1/Smad7 liver fibrosis in the hepatic stellate LX2 cell line and in CCl4-induced liver fibrosis in Sprague-Dawley rats.
|
29311932 |
2017 |
|
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, mice lacking miR-21 show increased Smad-7 expression, which may be driving the decrease in biliary hyperplasia and hepatic fibrosis.
|
27775690 |
2016 |
|
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the NTSD treatment significantly decreased the transforming growth factor beta 1 (TGF-β1) and Smad3 gene expression and increased inhibitory Smad7 gene expression in liver tissues of HF rats, suggesting that NTSD inhibited the ECM expression of HSC by downregulating the TGF-β1/Smad signaling pathway.
|
27633729 |
2016 |
|
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
More importantly, the present study showed HDAC2 may regulate HSCs activation by suppressing expression of Smad7, which is a negative modulator in HSCs activation and liver fibrosis.
|
27396813 |
2016 |
|
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased miR-16 expression induced by hepatitis C virus infection promotes liver fibrosis through downregulation of hepatocyte growth factor and Smad7.
|
26071245 |
2015 |
|
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The time course of the various actors of the TGF-β/Smad system in the in vivo mouse model as well as down-regulation of Smad7 in liver areas close to the lesions in human cases highly suggest that TGF-β plays an important role in AE both in immune tolerance against the parasite and in liver fibrosis.
|
23405141 |
2013 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Smurf2 interacts with Smad7 to suppress TGF-β-mediated liver fibrosis through the ubiquitin-dependent degradation of TβRI during the early period of liver fibrosis.
|
22624557 |
2012 |
|
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of the study was to determine whether Smad7 mRNA expression correlates with the gene expression of TGF-beta, Col I, Col III, Col IV, or PAI-1 in liver fibrosis secondary to bile duct injury (BDI).
|
19878580 |
2009 |